Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Encephalomyelitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Encephalomyelitis - Pipeline Review, H2 2014', provides an overview of the Encephalomyelitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Encephalomyelitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Encephalomyelitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Encephalomyelitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Encephalomyelitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Encephalomyelitis Overview 7 Therapeutics Development 8 Pipeline Products for Encephalomyelitis - Overview 8 Pipeline Products for Encephalomyelitis - Comparative Analysis 9 Encephalomyelitis - Therapeutics under Development by Companies 10 Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 12 Encephalomyelitis - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Encephalomyelitis - Products under Development by Companies 15 Encephalomyelitis - Products under Investigation by Universities/Institutes 16 Encephalomyelitis - Companies Involved in Therapeutics Development 17 Cognosci, Inc. 17 Endocyte, Inc. 18 Immune Technologies and Medicine 19 InteKrin Therapeutics, Inc. 20 Io Therapeutics, Inc. 21 KAHR medical Ltd. 22 Meiji Seika Pharma Co., Ltd. 23 Merck & Co., Inc. 24 Momenta Pharmaceuticals, Inc. 25 Novartis AG 26 PsiOxus Therapeutics, Ltd. 27 Encephalomyelitis - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 Anatabine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 COG-112 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 COG-133 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CP-9531 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 EC-1496 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 FSDC-10 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 INT-131 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 IRX-5183 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KAHR-101 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 KAHR-104 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 NIBR-0213 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 PETIR-001 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 SCH-546738 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule to Agonize Toll-Like Receptor for Venezuelan Equine Encephalitis - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 thymulin - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Encephalomyelitis - Recent Pipeline Updates 57 Encephalomyelitis - Dormant Projects 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Encephalomyelitis, H2 2014 8 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Encephalomyelitis - Pipeline by Cognosci, Inc., H2 2014 17 Encephalomyelitis - Pipeline by Endocyte, Inc., H2 2014 18 Encephalomyelitis - Pipeline by Immune Technologies and Medicine, H2 2014 19 Encephalomyelitis - Pipeline by InteKrin Therapeutics, Inc., H2 2014 20 Encephalomyelitis - Pipeline by Io Therapeutics, Inc., H2 2014 21 Encephalomyelitis - Pipeline by KAHR medical Ltd., H2 2014 22 Encephalomyelitis - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 23 Encephalomyelitis - Pipeline by Merck & Co., Inc., H2 2014 24 Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 25 Encephalomyelitis - Pipeline by Novartis AG, H2 2014 26 Encephalomyelitis - Pipeline by PsiOxus Therapeutics, Ltd., H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Number of Products by Stage and Target, H2 2014 30 Number of Products by Stage and Mechanism of Action, H2 2014 32 Number of Products by Stage and Route of Administration, H2 2014 34 Number of Products by Stage and Molecule Type, H2 2014 36 Encephalomyelitis Therapeutics - Recent Pipeline Updates, H2 2014 57 Encephalomyelitis - Dormant Projects, H2 2014 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
